A double-blinded, randomized controlled clinical trial of hydrogen inhalation therapy for idiopathic sudden sensorineural hearing loss.
Masahiro Okada, Hideo Ogawa, Taro Takagi, Eriko Nishihara, Tadashi Yoshida, Jun Hyodo, Yusuke Shinomori, Nobumitsu Honda, Takashi Fujiwara, Masato Teraoka, Hiroyuki Yamada, Shin-Ichi Hirano, Naohito Hato · Frontiers in neuroscience · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In participants with ISSNHL to receive either H₂ (H₂ group) or air as a placebo (control group) through inhalation combined with the administ, the hearing threshold 3 months after treatment was not significantly different between the groups; 39.0 decibels (dB) (95% confidence interval [CI]: 28.7-49.3) and 49.5 dB (95% CI: 40.3-58.7) in the H₂ and control groups, respectively.
What the Researchers Studied
Thus, the researchers investigated whether H₂ is effective for the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL).
How the Study Was Conducted
Randomized, double-blind, placebo-controlled human clinical trial.
How Molecular Hydrogen Was Used
The researchers randomly assigned patients with ISSNHL to receive either H₂ (H₂ group) or air as a placebo (control group) through inhalation combined with the administration of systemic glucocorticoids and prostaglandin E1.
What the Researchers Found
The hearing threshold 3 months after treatment was not significantly different between the groups; 39.0 decibels (dB) (95% confidence interval [CI]: 28.7-49.3) and 49.5 dB (95% CI: 40.3-58.7) in the H₂ and control groups, respectively.
Authors’ Conclusion
The authors concluded that this is the first study to investigate the efficacy of H₂ for the treatment of ISSNHL in humans.